Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IDH Mutation Clear all
Completed Phase 1Phase 2 Interventional Results available

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

NCT02719574
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
FT-2102 (olutasidenib), Azacitidine, Cytarabine
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
19
States / cities
Los Angeles, California • Sacramento, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Active, not recruiting Phase 1 Interventional

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

NCT02632708
View directory record Official record
Conditions
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising After Exposure to Genotoxic Injury
Interventions
AG-120, AG-221, cytarabine, daunorubicin, idarubicin, mitoxantrone, etoposide
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Recruiting Phase 1 Interventional

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

NCT02074839
View directory record Official record
Conditions
Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Interventions
AG-120
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

NCT04603001
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
Interventions
LY3410738, Venetoclax, Azacitidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Recruiting Not applicable Interventional

Non-invasive Glioma Characterization Through Molecular Imaging

NCT03684109
View directory record Official record
Conditions
Glioma, Brain Tumor, Primary Brain Tumor, Malignant Glioma, Malignant Primary Brain Tumor
Interventions
3T MRI Scanner
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Recruiting Phase 2 Interventional

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

NCT07301268
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Astrocytoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pembrolizumab, Surgical Procedure
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Recruiting Phase 2 Interventional

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

NCT05345002
View directory record Official record
Conditions
Glioma, IDH Mutation, Astrocytoma, Oligodendroglioma
Interventions
Retifanlimab, All-trans retinoic acid
Drug
Lead sponsor
Stephen Bagley, MD, MSCE
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Completed Early Phase 1 Interventional

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

NCT05851378
View directory record Official record
Conditions
Adult Gliomas, Mixed
Interventions
Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG), Magnetic Resonance Image (MRI)
Drug · Procedure
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

NCT02677922
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AG-120, Azacitidine, AG-221
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
9
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

NCT03953898
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Orange, California • New Haven, Connecticut • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Recruiting Phase 2 Interventional

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

NCT05401097
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biopsy, Enasidenib, Ivosidenib, Venetoclax
Drug · Procedure
Lead sponsor
Alice Mims
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Not yet recruiting Phase 1 Interventional

VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations

NCT07629089
View directory record Official record
Conditions
Brain Cancer
Interventions
Vorasidenib, Lomustine
Drug
Lead sponsor
Megan Mantica
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Recruiting Phase 1 Interventional

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

NCT07089641
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Active, not recruiting Early Phase 1 Interventional

Niraparib In Recurrent IDH 1/2 Gliomas

NCT05406700
View directory record Official record
Conditions
Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma, IDH1 Mutation, Glioma, Malignant
Interventions
Niraparib, Resection/Treatment with Niraparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

NCT06478212
View directory record Official record
Conditions
IDH1-mutant Glioma, IDH2-mutant Glioma
Interventions
Vorasidenib, Temozolomide (TMZ)
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
12 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Recruiting Phase 1 Interventional

Chronic CED of TPT for Recurrent Malignant Glioma

NCT06666712
View directory record Official record
Conditions
Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV), IDH1/IDH2 Mutation
Interventions
Topotecan
Drug
Lead sponsor
Jeffrey N. Bruce
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

NCT02381886
View directory record Official record
Conditions
Advanced Malignancies That Harbor IDHR132 Mutations
Interventions
IDH305
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Recruiting Phase 3 Interventional

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

NCT07215910
View directory record Official record
Conditions
Astrocytoma, IDH-Mutant, Grade 3
Interventions
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning, Intensity-Modulated Proton Therapy, Temozolomide, Vorasidenib, Placebo Administration, Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration
Radiation · Procedure · Drug + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
12 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
152
States / cities
Bakersfield, California • Duarte, California • Dublin, California + 119 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Active, not recruiting Phase 1 Interventional

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

NCT03749187
View directory record Official record
Conditions
Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions
PARP Inhibitor BGB-290, Temozolomide (TMZ)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 39 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

NCT02273739
View directory record Official record
Conditions
Solid Tumor, Glioma, Angioimmunoblastic T-cell Lymphoma, Intrahepatic Cholangiocarcinoma, Chondrosarcoma
Interventions
Enasidenib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 21, 2026, 2:39 AM EDT
Terminated Phase 1 Interventional Results available

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

NCT04762602
View directory record Official record
Conditions
Isocitrate Dehydrogenase Gene Mutation
Interventions
HMPL-306
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Recruiting Phase 1Phase 2 Interventional

000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

NCT05588141
View directory record Official record
Conditions
Brain Tumor, Cancer
Interventions
Zotiraciclib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 99 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 2:39 AM EDT
Withdrawn Phase 1 Interventional

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

NCT04955938
View directory record Official record
Conditions
IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation, Blood Cancer, Myeloproliferative Neoplasm
Interventions
Ivosidenib, Enasidenib, Fedratinib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 21, 2026, 2:39 AM EDT
Terminated Phase 1 Interventional Results available

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

NCT04764474
View directory record Official record
Conditions
Isocitrate Dehydrogenase Gene Mutation
Interventions
HMPL-306
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Orange, California • Atlanta, Georgia • Worcester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 21, 2026, 2:39 AM EDT